{"id":390805,"date":"2017-12-12T00:00:00","date_gmt":"2017-12-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0012-2017-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-14T10:27:06","modified_gmt":"2026-04-14T10:27:06","slug":"dlsfon0012-2017-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0012-2017-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Bladder Cancer | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p><strong>Market Outlook:<\/strong><\/p>\n<p>Immune checkpoint inhibitors are revolutionizing the treatment algorithm for the unresectable locally advanced or metastatic bladder cancer. With the 2016\/7 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients (i.e., second\u2013 and later lines), PD-L1 inhibitor Tecentriq (Roche\/Genentech) first followed by PD-1 inhibitor Opdivo (Bristol-Myers Squibb) and other PD-1\/PD-L1 inhibitors, significant sales are forecast to be generated in the unresectable locally advanced or metastatic setting. There is now intense phase II\/III pipeline activity, with some drugs in late-phase pipeline also targeting previously-untreated unresectable locally advanced or metastatic bladder cancer (i.e., first-line setting). We anticipate that several new therapies will gain approvals within the forecast period, resulting in increased therapy options for patients.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<p>How large are the clinically and commercially relevant drug-treatable unresectable locally advanced or metastatic bladder cancer populations and how will drug-treatment rates change over time?<\/p>\n<p>What is the current state of treatment for unresectable locally advanced or metastatic bladder cancer?<\/p>\n<p>What are the (dis)advantages of currently marketed drugs and interviewed experts\u2019 insights on these therapies?<\/p>\n<p>What clinical needs remain unfulfilled and what opportunities can developers capitalize on?<\/p>\n<p>What pipeline products are most promising, and what sales\/uptake could they secure in the unresectable locally advanced or metastatic bladder cancer market?<\/p>\n<p>What are the most promising early-phase pipeline products?<\/p>\n<p>What are the drivers and constraints in the unresectable bladder cancer market, and how will the market evolve over the 10-year forecast period within the major markets?<\/p>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390805","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390805\/revisions"}],"predecessor-version":[{"id":393929,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390805\/revisions\/393929"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}